Astellas' OSI subsidiary granted PanOptica exclusive, worldwide rights to PAN-90806 for ophthalmic indications

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

PanOptica Inc.

U.S. / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced